FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W416320400> ?p ?o ?g. }

• W416320400 endingPage "596" @default.
• W416320400 startingPage "583" @default.
• W416320400 abstract "In this work, we aimed to identify molecular epidermal growth factor receptor (EGFR) tissue biomarkers in patients with ovarian cancer who were treated within the phase III randomized European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group (EORTC-GCG) 55041 study comparing erlotinib with observation in patients with no evidence of disease progression after first-line platinum-based chemotherapy.Somatic mutations in KRAS, BRAF, NRAS, PIK3CA, EGFR, and PTEN were determined in 318 (38 %) and expression of EGFR, pAkt, pMAPK, E-cadherin and Vimentin, and EGFR and HER2 gene copy numbers in 218 (26 %) of a total of 835 randomized patients. Biomarker data were correlated with progression-free survival (PFS) and overall survival (OS).Only 28 mutations were observed among KRAS, BRAF, NRAS, PIK3CA, EGFR, and PTEN (in 7.5 % of patients), of which the most frequent were in KRAS and PIK3CA. EGFR mutations occurred in only three patients. When all mutations were pooled, patients with at least one mutation in KRAS, NRAS, BRAF, PIK3CA, or EGFR had longer PFS (33.1 versus 12.3 months; HR 0.57; 95 % CI 0.33 to 0.99; P = 0.042) compared to those with wild-type tumors. EGFR overexpression was detected in 93 of 218 patients (42.7 %), and 66 of 180 patients (36.7 %) had EGFR gene amplification or high levels of copy number gain. Fifty-eight of 128 patients had positive pMAPK expression (45.3 %), which was associated with inferior OS (38.9 versus 67.0 months; HR 1.81; 95 % CI 1.11 to 2.97; P = 0.016). Patients with positive EGFR fluorescence in situ hybridization (FISH) status had worse OS (46.1 months) than those with negative status (67.0 months; HR 1.56; 95 % CI 1.01 to 2.40; P = 0.044) and shorter PFS (9.6 versus 16.1 months; HR 1.57; 95 % CI 1.11 to 2.22; P = 0.010). None of the investigated biomarkers correlated with responsiveness to erlotinib.In this phase III study, increased EGFR gene copy number was associated with worse OS and PFS in patients with ovarian cancer. It remains to be determined whether this association is purely prognostic or is also predictive." @default.
• W416320400 created "2016-06-24" @default.
• W416320400 creator A5007992309 @default.
• W416320400 creator A5017298616 @default.
• W416320400 creator A5024045160 @default.
• W416320400 creator A5029949952 @default.
• W416320400 creator A5036818390 @default.
• W416320400 creator A5041555565 @default.
• W416320400 creator A5049908989 @default.
• W416320400 creator A5058535647 @default.
• W416320400 creator A5058849373 @default.
• W416320400 creator A5060123097 @default.
• W416320400 creator A5066990182 @default.
• W416320400 creator A5071851332 @default.
• W416320400 creator A5073713547 @default.
• W416320400 creator A5076548846 @default.
• W416320400 creator A5078760536 @default.
• W416320400 creator A5081418446 @default.
• W416320400 date "2015-05-26" @default.
• W416320400 modified "2023-09-27" @default.
• W416320400 title "Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy" @default.
• W416320400 cites W101504470 @default.
• W416320400 cites W1964321121 @default.
• W416320400 cites W1965850768 @default.
• W416320400 cites W1966889884 @default.
• W416320400 cites W1970232026 @default.
• W416320400 cites W1974028385 @default.
• W416320400 cites W1988442083 @default.
• W416320400 cites W1989051196 @default.
• W416320400 cites W1989773675 @default.
• W416320400 cites W1998258610 @default.
• W416320400 cites W2013498672 @default.
• W416320400 cites W2028662865 @default.
• W416320400 cites W2034338421 @default.
• W416320400 cites W2034642746 @default.
• W416320400 cites W2041919461 @default.
• W416320400 cites W2043696829 @default.
• W416320400 cites W2055654338 @default.
• W416320400 cites W2062051005 @default.
• W416320400 cites W2075668200 @default.
• W416320400 cites W2077422669 @default.
• W416320400 cites W2085739259 @default.
• W416320400 cites W2099521317 @default.
• W416320400 cites W2100589633 @default.
• W416320400 cites W2101830631 @default.
• W416320400 cites W2103441770 @default.
• W416320400 cites W2105453387 @default.
• W416320400 cites W2106983577 @default.
• W416320400 cites W2108187449 @default.
• W416320400 cites W2111584304 @default.
• W416320400 cites W2118004874 @default.
• W416320400 cites W2119180969 @default.
• W416320400 cites W2119646041 @default.
• W416320400 cites W2122885616 @default.
• W416320400 cites W2123027432 @default.
• W416320400 cites W2128059540 @default.
• W416320400 cites W2131413118 @default.
• W416320400 cites W2134142320 @default.
• W416320400 cites W2134519717 @default.
• W416320400 cites W2138604360 @default.
• W416320400 cites W2139236349 @default.
• W416320400 cites W2139248078 @default.
• W416320400 cites W2148930326 @default.
• W416320400 cites W2156647409 @default.
• W416320400 cites W2157824687 @default.
• W416320400 cites W2158475201 @default.
• W416320400 cites W2158863975 @default.
• W416320400 cites W2160866033 @default.
• W416320400 cites W2161821474 @default.
• W416320400 cites W2165119042 @default.
• W416320400 cites W2168656450 @default.
• W416320400 cites W2252397189 @default.
• W416320400 cites W2437177400 @default.
• W416320400 cites W3028515504 @default.
• W416320400 cites W4233920089 @default.
• W416320400 doi "https://doi.org/10.1007/s11523-015-0369-6" @default.
• W416320400 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4661131" @default.
• W416320400 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27056749" @default.
• W416320400 hasPublicationYear "2015" @default.
• W416320400 type Work @default.
• W416320400 sameAs 416320400 @default.
• W416320400 citedByCount "19" @default.
• W416320400 countsByYear W4163204002015 @default.
• W416320400 countsByYear W4163204002016 @default.
• W416320400 countsByYear W4163204002017 @default.
• W416320400 countsByYear W4163204002018 @default.
• W416320400 countsByYear W4163204002019 @default.
• W416320400 countsByYear W4163204002020 @default.
• W416320400 countsByYear W4163204002021 @default.
• W416320400 countsByYear W4163204002022 @default.
• W416320400 countsByYear W4163204002023 @default.
• W416320400 crossrefType "journal-article" @default.
• W416320400 hasAuthorship W416320400A5007992309 @default.
• W416320400 hasAuthorship W416320400A5017298616 @default.
• W416320400 hasAuthorship W416320400A5024045160 @default.
• W416320400 hasAuthorship W416320400A5029949952 @default.
• W416320400 hasAuthorship W416320400A5036818390 @default.
• W416320400 hasAuthorship W416320400A5041555565 @default.

• next